Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Illumina, Inc. (ILMN) vs TJX Companies Inc (TJX) Price & Performance

Illumina, Inc.Trade
TJX Companies IncTrade

Price performance (Past 24H)

Key statistics

Illumina, Inc. vs TJX Companies Inc — how do they compare? Illumina, Inc. trades at $190.45 (market cap $27.94B), while TJX Companies Inc trades at $153.04 (market cap $172.00B). The key difference: TJX Companies Inc is far larger — about 6.2× Illumina, Inc.'s market cap, and TJX Companies Inc pays a 1.23% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.

ILMNTJX
Market Cap
$27.94B$172.00B
Sector
HealthConsumer Cyclical
52-Week High
$194.33$168.41
52-Week Low
$91.00$124.53
Enterprise Value
$29.33B$180.60B
Dividend Yield
1.23%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Illumina, Inc.

Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.

Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.

TJX Companies Inc

TJX trades at $155.47, up 0.7% on the day, with a bullish technical signal and strong fundamental performance. The company has consistently beaten earnings expectations, with Q1 2026 EPS of $1.19 surpassing the $1.02 estimate. Revenue growth is robust, reaching $56.36 billion in 2025, with a net income margin of 9.4%. Analyst sentiment is overwhelmingly positive, with 88% recommending Buy and a consensus price target of $181.80, suggesting significant upside potential from current levels.

The outlook for TJX remains favorable, driven by sustained earnings beats, expanding margins, and strategic international growth. Key risks include competitive pressures in discount retail and sensitivity to consumer spending trends. With strong cash flow generation supporting dividends and buybacks, TJX presents a compelling growth story, though valuation metrics like a P/E of 30.05 warrant monitoring for overextension.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Illumina, Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Read more on ILMN

About TJX Companies Inc

TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.

Read more on TJX